- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:38 | Sharp Therapeutics Corp. Reports Third Quarter 2025 Results and Development Update | 167 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - November 26, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), announces the release of its condensed... ► Artikel lesen | |
| 14.10. | Sharp Therapeutics Corp.: Sharp Therapeutics Arranges Non-Brokered Private Placement | 300 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - October 14, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company"), is pleased to announce that it... ► Artikel lesen | |
| SHARP THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 08.10. | Sharp Therapeutics to Present Pipeline and Program Updates at World Orphan Drug Congress 2025 | 1 | GlobeNewswire (USA) | ||
| 30.08. | Sharp Therapeutics Corp (2): Sharp Therapeutics begins trading on OTCQB | 2 | Stockwatch | ||
| 29.08. | Sharp Therapeutics Corp. Reports Second Quarter 2025 Results and Expands Market Presence with Listing On OTCQB | 392 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - August 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its condensed... ► Artikel lesen | |
| 30.07. | Sharp Therapeutics Corp (2): Sharp hires Rho for drug application submission to FDA | 1 | Stockwatch | ||
| 29.07. | Sharp Therapeutics Corp. Engages Rho Inc. to Help Advance Compounds into Clinical Trials for Gaucher Disease | 449 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 29, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a preclinical-stage biotechnology company developing... ► Artikel lesen | |
| 22.07. | Sharp Therapeutics Corp (2): Sharp Therapeutics shareholders approve AGM resolutions | 2 | Stockwatch | ||
| 21.07. | Sharp Therapeutics Corp. Announces Results from Annual Meeting of Shareholders | 327 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - July 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical biotechnology company developing small... ► Artikel lesen | |
| 22.05. | Sharp Therapeutics Corp. Reports First Quarter 2025 Results | 380 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 22, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 13.05. | Sharp Therapeutics Corp. Nominates Clinical Candidate for Gaucher's Disease | 392 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - May 13, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 21.04. | STX PARTNERS LLP and Newlin Investment Co. Exercise Warrants of Sharp Therapeutics Corp. | 361 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 21, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical-stage biotechnology company developing... ► Artikel lesen | |
| 27.01. | Sharp Therapeutics Corp. Completes Share Consolidation | 389 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 27, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
| 16.01. | Sharp Therapeutics Corp. Announces Share Consolidation | 297 | Newsfile | Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - January 16, 2025) - Sharp Therapeutics Corp. (TSXV: SHRX) ("Sharp" or the "Company"), a pre-clinical stage biotechnology company specializing... ► Artikel lesen | |
| 12.12.24 | Sharp Therapeutics Corp. Announces Completion of Qualifying Transaction | 345 | Newsfile | Toronto, Ontario--(Newsfile Corp. - December 12, 2024) - Sharp Therapeutics Corp. (TSXV: EVP.P) ("Sharp Therapeutics"), formerly EVP Capital Inc. ("EVP Capital"), an Ontario corporation is pleased... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| COGENT BIOSCIENCES | 40,390 | +1,69 % | Will Cogent Biosciences' (COGT) Breakthrough Therapy Transform GIST Treatment? Analysts Think So | ||
| NUVALENT | 109,06 | -0,70 % | Nuvalent, Inc.: Nuvalent Announces FDA Acceptance of New Drug Application for Zidesamtinib for the Treatment of TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | NDA based on data from global ARROS-1 Phase 1/2 clinical trial
FDA assigns PDUFA target action date of September 18, 2026
CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/... ► Artikel lesen | |
| VERA THERAPEUTICS | 33,330 | +13,25 % | Vera Therapeutics: Aktie laut Analysten unterbewertet - starkes Potenzial im IgAN-Markt | ||
| QIAGEN | 41,775 | -0,04 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 71,59 | +0,06 % | Novartis CEO paid top dollar for Avidity to become a 'leader in neuromuscular diseases' | ||
| OLEMA PHARMACEUTICALS | 28,110 | +7,83 % | Biotech-Party! Olema-Aktie explodiert über 136 Prozent - die Hintergründe | Prämie dank Übernahme? Spektakuläre Studienergebnisse? Es ist keine Seltenheit, dass Biotech-Titel aus dem Stand an einem Tag prozentual dreistellig an Wert gewinnen können. Bei Olema Pharmaceuticals... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 188,52 | +2,32 % | Praxis Precision Medicines, Inc.: Praxis to present latest preclinical and clinical advancements across leading epilepsy portfolio at the 2025 American Epilepsy Society (AES) Annual Meeting | ||
| ADMA BIOLOGICS | 19,150 | -0,31 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| IMMUNOVANT | 23,700 | -1,04 % | Immunovant, Inc. - 8-K, Current Report | ||
| BEAM THERAPEUTICS | 25,030 | +1,34 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| DYNE THERAPEUTICS | 21,180 | +1,83 % | Dyne Therapeutics: Bernstein hebt Kursziel wegen günstigem Risiko-Ertrags-Verhältnis an | ||
| TREVI THERAPEUTICS | 13,295 | +17,03 % | Leerink Partners raises Trevi Therapeutics stock price target to $16 on Haduvio outlook | ||
| ARCELLX | 73,24 | +0,33 % | Arcellx: Stifel bekräftigt "Buy"-Rating im Vorfeld der ASH-Konferenz 2025 | ||
| NURIX THERAPEUTICS | 17,200 | +1,12 % | Nurix Therapeutics, Inc.: Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 30,950 | +0,72 % | Why Shares in Arcutis Biotherapeutics Surged Again This Week |
Das Unternehmen SHARP THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHARP THERAPEUTICS CORP finden Sie auf Wallstreet Online.